Incidence, risk factors, and outcomes of stroke post‐transplantation in patients receiving a steroid sparing immunosuppression protocol
Adult
Graft Rejection
Male
610
Kaplan-Meier Estimate
03 medical and health sciences
Postoperative Complications
0302 clinical medicine
Adrenal Cortex Hormones
Risk Factors
616
Odds Ratio
Humans
Aged
Retrospective Studies
Incidence
Middle Aged
Kidney Transplantation
3. Good health
Stroke
Logistic Models
Treatment Outcome
Pancreas Transplantation
Immunosuppressive Agents
Follow-Up Studies
DOI:
10.1111/ctr.12476
Publication Date:
2014-10-10T14:24:00Z
AUTHORS (7)
ABSTRACT
AbstractCorticosteroid use after transplantation is associated with an increased incidence of cardiovascular events and death. Cerebrovascular disease is a common cause of morbidity and mortality post‐renal transplantation; however, a dedicated analysis of cerebrovascular disease in recipients of a steroid sparing protocol has not been reported. The aim of this study was to examine the incidence, risk factors, and outcomes of CVA in transplant recipients receiving a steroid sparing protocol. We retrospectively analyzed 1237 patients who received a kidney alone or a simultaneous pancreas and kidney (SPK) transplant. Fifty‐six of 1237 (4.53%) patients had a CVA post‐transplant. All‐cause mortality was significantly higher in the CVA group compared with the non‐CVA group, OR: 3.4 (1.7–7.0), p < 0.001. Factors found to be associated with increased risk of CVA by multivariate analysis were older age, HR: 1.07 (1.04–1.09), p < 0.001; diabetes at the time of transplantation, HR: 2.83 (1.42–5.64), p = 0.003; corticosteroid use pre‐transplant, HR: 3.27 (1.29–8.27), p = 0.013 and recipients of a SPK, HR: 4.03 (1.85–8.79), p < 0.001. This study has identified subgroups of patients who are at increased risk of CVA post‐transplant in patients otherwise receiving a steroid sparing immunosuppression protocol.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (33)
CITATIONS (13)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....